SynthesisPediatric surgery international2025
Serum matrix metalloproteinase-7 (MMP-7) as a Biomarker for differentiating biliary atresia from neonatal hepatitis: evidence synthesis through systematic review and meta-analysis.
Synthesis in Pediatric surgery international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBiliary atresia (BA) requires timely differentiation from neonatal hepatitis (NH) and early surgery for optimal outcomes. This systematic review and meta-analysis evaluated the diagnostic performance of serum Matrix metalloproteinase-7 (MMP-7) as a biomarker for differentiating BA from NH.
methodsThe PRISMA-DTA compliant synthesis was based upon primary data available till date, assessing the role of MMP-7 in diagnosing BA. Studies reporting diagnostic accuracy metrics were included. Pooled sensitivity, specificity, likelihood ratios, diagnostic odds ratio (DOR) and area under the summary receiver operating characteristic (SROC) curve were calculated.
resultsTwenty-four studies (7298 participants: 3301 BA, 2,930 NH and 1067 controls) were analysed. The serum MMP-7 values ranged from 1.2 to 10.3 ng/mL in controls, 1.88-12.57 ng/mL in NH and 10.26-121.1 ng/mL in BA, with interquartile ranges spanning 1.08-25.3, 0.78-34.0 and 3.38-368.0 ng/mL, respectively. Median serum MMP-7 levels were consistently higher in BA vis-a-vis NH and the control population. Pooled sensitivity and specificity of MMP-7 as a diagnostic biomarker were 0.94 and 0.88, respectively. The DOR was 120.09 and the SROC AUC was 0.967.
conclusionSerum MMP-7 demonstrates excellent diagnostic accuracy for differentiating BA from NH. Further research should focus on assay standardization and age-specific reference ranges to optimize clinical utility.
Indexed as
Identifiers
40849391What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.